ES2580379T3 - Biomarcadores de microARN indicativos de la enfermedad de Alzheimer - Google Patents
Biomarcadores de microARN indicativos de la enfermedad de Alzheimer Download PDFInfo
- Publication number
- ES2580379T3 ES2580379T3 ES12750628.5T ES12750628T ES2580379T3 ES 2580379 T3 ES2580379 T3 ES 2580379T3 ES 12750628 T ES12750628 T ES 12750628T ES 2580379 T3 ES2580379 T3 ES 2580379T3
- Authority
- ES
- Spain
- Prior art keywords
- mirna
- mir
- sample
- disease
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 26
- 239000000090 biomarker Substances 0.000 title description 27
- 108700011259 MicroRNAs Proteins 0.000 title 1
- 108091070501 miRNA Proteins 0.000 abstract description 143
- 239000002679 microRNA Substances 0.000 abstract description 139
- 238000000034 method Methods 0.000 abstract description 56
- 108091031326 miR-15b stem-loop Proteins 0.000 abstract description 15
- 108091033433 MiR-191 Proteins 0.000 abstract description 10
- 108091007427 let-7g Proteins 0.000 abstract description 10
- 210000001175 cerebrospinal fluid Anatomy 0.000 abstract description 8
- 108091033753 let-7d stem-loop Proteins 0.000 abstract description 7
- 108091079658 miR-142-1 stem-loop Proteins 0.000 abstract description 7
- 108091071830 miR-142-2 stem-loop Proteins 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 208000010877 cognitive disease Diseases 0.000 abstract 3
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 89
- 230000003321 amplification Effects 0.000 description 24
- 238000003199 nucleic acid amplification method Methods 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 20
- 238000005516 engineering process Methods 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 19
- 150000007523 nucleic acids Chemical group 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 239000012472 biological sample Substances 0.000 description 13
- 108091040490 miR-545 stem-loop Proteins 0.000 description 13
- 238000002493 microarray Methods 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 108091029203 miR-301 stem-loop Proteins 0.000 description 11
- 108091026505 miR-301a stem-loop Proteins 0.000 description 11
- 238000003753 real-time PCR Methods 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 238000013145 classification model Methods 0.000 description 7
- 238000010839 reverse transcription Methods 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000000636 Northern blotting Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 108091064157 miR-106a stem-loop Proteins 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007635 classification algorithm Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- -1 for example Substances 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003253 miRNA assay Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 108091043994 let-7g stem-loop Proteins 0.000 description 2
- 108091053972 let-7g-1 stem-loop Proteins 0.000 description 2
- 108091024867 let-7g-2 stem-loop Proteins 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 235000009027 Amelanchier alnifolia Nutrition 0.000 description 1
- 244000068687 Amelanchier alnifolia Species 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108091028066 Mir-126 Proteins 0.000 description 1
- 238000011495 NanoString analysis Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 206010060854 Post lumbar puncture syndrome Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- OTXOHOIOFJSIFX-POYBYMJQSA-N [[(2s,5r)-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)O)CC[C@@H]1N1C(=O)NC(=O)C=C1 OTXOHOIOFJSIFX-POYBYMJQSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000003066 decision tree Methods 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000005518 electrochemistry Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108091060293 miR-453 stem-loop Proteins 0.000 description 1
- 108091084213 miR-563 stem-loop Proteins 0.000 description 1
- 108091023451 miR-600 stem-loop Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000010238 partial least squares regression Methods 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012628 principal component regression Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012706 support-vector machine Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- AVBGNFCMKJOFIN-UHFFFAOYSA-N triethylammonium acetate Chemical compound CC(O)=O.CCN(CC)CC AVBGNFCMKJOFIN-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501720P | 2011-06-27 | 2011-06-27 | |
| US201161501720P | 2011-06-27 | ||
| PCT/US2012/044202 WO2013003350A2 (en) | 2011-06-27 | 2012-06-26 | Microrna biomarkers indicative of alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2580379T3 true ES2580379T3 (es) | 2016-08-23 |
Family
ID=46724591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12750628.5T Active ES2580379T3 (es) | 2011-06-27 | 2012-06-26 | Biomarcadores de microARN indicativos de la enfermedad de Alzheimer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9771617B2 (enExample) |
| EP (1) | EP2723894B1 (enExample) |
| JP (2) | JP6154809B2 (enExample) |
| KR (1) | KR102082016B1 (enExample) |
| CN (1) | CN103781919B9 (enExample) |
| AU (1) | AU2012275556B2 (enExample) |
| BR (1) | BR112013033488B8 (enExample) |
| CA (1) | CA2840196C (enExample) |
| ES (1) | ES2580379T3 (enExample) |
| IL (1) | IL230034B (enExample) |
| MX (1) | MX341840B (enExample) |
| RU (1) | RU2639509C2 (enExample) |
| WO (1) | WO2013003350A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013022953A2 (en) * | 2011-08-08 | 2013-02-14 | Eugenia Wang | Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof |
| WO2015050835A1 (en) * | 2013-10-01 | 2015-04-09 | Advanced Genomic Technology, Llc | Circulating biomarkers for alzheimer's disease and/or mild cognitive impairment |
| WO2015134551A1 (en) * | 2014-03-03 | 2015-09-11 | Banyan Biomarkers, Inc. | Micro rna markers for diagnosis of a neurological condition |
| KR101583450B1 (ko) * | 2014-12-01 | 2016-01-11 | 전주대학교 산학협력단 | 마이크로 rna id의 분석방법 및 이를 통해 도출한 대장암의 바이오마커 |
| EP3269823B1 (en) | 2015-03-13 | 2019-06-05 | Hiroshima University | Method for assisting detection of alzheimer's disease or mild cognitive impairment |
| US10358676B2 (en) * | 2015-04-03 | 2019-07-23 | Kaohsiung Chang Gung Memorial Hospital | Methods and kits for detecting Kawasaki disease |
| KR101734645B1 (ko) * | 2015-05-18 | 2017-05-11 | (주)에이엔티랩스 | 초기 알츠하이머 병 또는 경도 인지 장애 진단 방법 |
| EP4424704A3 (en) | 2015-09-16 | 2024-12-25 | Shimadzu Corporation | Multiplex biomarker for use in evaluation of state of accumulation of amyloid b in brain, and analysis method for said evaluation |
| EP3184646B1 (de) * | 2015-12-22 | 2019-04-17 | Siemens Aktiengesellschaft | Spezifische signaturen in alzheimer durch multizentrische mirna-profile |
| US10262423B2 (en) * | 2016-03-29 | 2019-04-16 | Verily Life Sciences Llc | Disease and fall risk assessment using depth mapping systems |
| WO2017186719A1 (en) * | 2016-04-25 | 2017-11-02 | Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Polska Akademia Nauk | Microrna biomarkers in blood for diagnosis of alzheimer's disease |
| KR101998457B1 (ko) * | 2016-05-10 | 2019-07-10 | 조선대학교산학협력단 | 알츠하이머 질병의 진단을 위한 바이오마커 |
| KR101992539B1 (ko) * | 2016-10-21 | 2019-09-30 | 서울대학교산학협력단 | miRNA 기반의 인지장애 질환 진단용 조성물 및 방법 |
| WO2018228875A1 (en) * | 2017-06-15 | 2018-12-20 | Nestec S.A. | Micro-rna biomarkers of blood-brain barrier dysfunction |
| JP2020524509A (ja) * | 2017-06-19 | 2020-08-20 | セント・ジョーンズ・ユニバーシティＳｔ． Ｊｏｈｎｓ Ｕｎｉｖｅｒｓｉｔｙ | アルツハイマー病の診断のための循環血清マイクロｒｎａバイオマーカー及び方法 |
| CA3069445A1 (en) * | 2017-07-12 | 2019-01-17 | Texas Tech University System | Microrna-455-3p as a peripheral biomarker for alzheimer's disease |
| US11078535B2 (en) * | 2017-07-18 | 2021-08-03 | The Trustees Of Indiana University | Presymptomatic micro RNA targets for treatment of neurodegeneration pathology |
| CN111511929A (zh) * | 2017-10-25 | 2020-08-07 | 蜂鸟诊断有限责任公司 | 作为用于阿尔茨海默氏病的生物标志物的miRNA |
| WO2019094780A2 (en) * | 2017-11-12 | 2019-05-16 | The Regents Of The University Of California | Non-coding rna for detection of cancer |
| WO2019117306A1 (ja) | 2017-12-14 | 2019-06-20 | 国立大学法人広島大学 | アルツハイマー病の検出を補助する方法 |
| CN108277271A (zh) * | 2018-02-05 | 2018-07-13 | 范瑶飞 | 一种辅助检测阿兹海默疾病的miRNA |
| WO2019159884A1 (ja) * | 2018-02-13 | 2019-08-22 | 東レ株式会社 | 認知症の検出のためのキット又はデバイス及び方法 |
| US12054779B2 (en) | 2018-06-15 | 2024-08-06 | Universitat Autònoma De Barcelona | Circulating miRNAs as biomarkers for diagnosis of mild cognitive impairment and Alzheimer's disease |
| KR20210038585A (ko) * | 2018-07-25 | 2021-04-07 | 에스알엔에이리틱스, 인크. | 알츠하이머병에 대한 작은 rna 예측인자 |
| JP6884810B2 (ja) * | 2019-05-08 | 2021-06-09 | キユーピー株式会社 | 情報提供装置、情報提供方法及びｍｉＲＮＡ重要度テーブル生成方法 |
| US20240093297A1 (en) * | 2020-07-24 | 2024-03-21 | Otago Innovation Limited | Biomarkers For Cognitive Conditions |
| WO2022165205A1 (en) * | 2021-01-29 | 2022-08-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Systems and methods for diagnosing neurodegenerative diseases |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| US5965364A (en) | 1990-10-09 | 1999-10-12 | Benner; Steven Albert | Method for selecting functional deoxyribonucleotide derivatives |
| US5767259A (en) | 1994-12-27 | 1998-06-16 | Naxcor | Oligonucleotides containing base-free linking groups with photoactivatable side chains |
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| AU713667B2 (en) | 1996-04-12 | 1999-12-09 | Phri Properties, Inc. | Detection probes, kits and assays |
| SE506700C2 (sv) | 1996-05-31 | 1998-02-02 | Mikael Kubista | Sond och förfaranden för analys av nukleinsyra |
| AU1366299A (en) | 1997-10-27 | 1999-05-17 | Boston Probes, Inc. | Methods, kits and compositions pertaining to pna molecular beacons |
| US6485901B1 (en) | 1997-10-27 | 2002-11-26 | Boston Probes, Inc. | Methods, kits and compositions pertaining to linear beacons |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6383752B1 (en) | 1999-03-31 | 2002-05-07 | Hybridon, Inc. | Pseudo-cyclic oligonucleobases |
| JP5064625B2 (ja) | 1999-10-27 | 2012-10-31 | バイオウルフ テクノロジーズ エルエルスィー | パターンを同定するための方法及び機械 |
| US6528254B1 (en) | 1999-10-29 | 2003-03-04 | Stratagene | Methods for detection of a target nucleic acid sequence |
| US6596490B2 (en) | 2000-07-14 | 2003-07-22 | Applied Gene Technologies, Inc. | Nucleic acid hairpin probes and uses thereof |
| WO2002006829A2 (en) | 2000-07-18 | 2002-01-24 | Correlogic Systems, Inc. | A process for discriminating between biological states based on hidden patterns from biological data |
| US6350580B1 (en) | 2000-10-11 | 2002-02-26 | Stratagene | Methods for detection of a target nucleic acid using a probe comprising secondary structure |
| US7113896B2 (en) | 2001-05-11 | 2006-09-26 | Zhen Zhang | System and methods for processing biological expression data |
| US7060809B2 (en) | 2001-09-04 | 2006-06-13 | Exiqon A/S | LNA compositions and uses thereof |
| US6593091B2 (en) | 2001-09-24 | 2003-07-15 | Beckman Coulter, Inc. | Oligonucleotide probes for detecting nucleic acids through changes in flourescence resonance energy transfer |
| US20020193950A1 (en) | 2002-02-25 | 2002-12-19 | Gavin Edward J. | Method for analyzing mass spectra |
| US20030225031A1 (en) * | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| JP2004161636A (ja) | 2002-11-11 | 2004-06-10 | Takeda Chem Ind Ltd | 軽度認知障害または注意欠陥多動性障害治療剤 |
| EP2267166B1 (en) | 2003-04-25 | 2016-01-13 | Becton Dickinson and Company | Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification |
| US9119846B2 (en) | 2003-04-29 | 2015-09-01 | Neurim Pharmaceuticals (1991) Ltd. | Method and composition for enhancing cognition in alzheimer's patients |
| AU2005271961B8 (en) | 2004-07-09 | 2011-11-24 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of markers in esophageal cancer, colon cancer, head and neck cancer and melanoma |
| US20060078894A1 (en) | 2004-10-12 | 2006-04-13 | Winkler Matthew M | Methods and compositions for analyzing nucleic acids |
| JP2006176503A (ja) | 2004-11-26 | 2006-07-06 | Tohoku Univ | 脳血管障害を伴うアルツハイマー病治療薬 |
| RU2418068C2 (ru) * | 2005-08-17 | 2011-05-10 | Сирна Терапьютикс, Инк. | Молекулы химически модифицированной короткой интерферирующей нуклеиновой кислоты, которые опосредуют интерференцию рнк |
| WO2007044937A2 (en) * | 2005-10-13 | 2007-04-19 | President And Fellows Of Harvard College | Compositions and methods to modulate memory |
| EP2056876A1 (en) * | 2006-08-21 | 2009-05-13 | Novartis AG | Biomarkers for alzheimer's disease progression |
| WO2008153692A2 (en) * | 2007-05-22 | 2008-12-18 | The Brigham And Women's Hospital, Inc. | Microrna expression profiling of cerebrospinal fluid |
| WO2008147839A1 (en) | 2007-05-23 | 2008-12-04 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| WO2009009457A1 (en) * | 2007-07-06 | 2009-01-15 | University Of Louisville Research Foundation, Inc. | Alzheimer's disease-specific micro-rna microarray and related methods |
| US8551703B2 (en) | 2007-07-06 | 2013-10-08 | The Regents Of The University Of California | SNPs associated with fatty acid composition of bovine meat and milk |
| GB2459228B (en) * | 2007-07-25 | 2012-06-20 | Univ Louisville Res Found | Exosome-associated microrna as a diagnostic marker |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| WO2009025852A2 (en) * | 2007-08-22 | 2009-02-26 | Xenomics, Inc. | Methods of using mirna for detection of in vivo cell death |
| BRPI0816852A2 (pt) * | 2007-09-14 | 2017-06-06 | Univ Ohio State Res Found | método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. |
| WO2009085200A2 (en) | 2007-12-21 | 2009-07-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
| US20110160290A1 (en) | 2008-05-21 | 2011-06-30 | Muneesh Tewari | Use of extracellular rna to measure disease |
| CN101386848A (zh) | 2008-08-12 | 2009-03-18 | 南京大学 | 细胞微粒子所载微小核糖核酸及其制备研究方法和应用 |
| EP2350320A4 (en) | 2008-11-12 | 2012-11-14 | Caris Life Sciences Luxembourg Holdings | METHOD AND SYSTEMS FOR USE OF EXOSOMES FOR THE DETERMINATION OF PHENOTYPES |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| EP2287336A1 (fr) | 2009-07-31 | 2011-02-23 | Exhonit Therapeutics SA | Procédés et méthodes de diagnostic de la maladie d'Alzheimer |
| AU2010294197C9 (en) * | 2009-09-10 | 2018-09-13 | Velin-Pharma A/S | Method for the preparation of micro-RNA and its therapeutic application |
| WO2011057003A2 (en) | 2009-11-04 | 2011-05-12 | Samuil Umansky | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
| GB201011420D0 (en) | 2010-07-06 | 2010-08-18 | United Arab Emirates Universit | Method for diagnosis |
| EP2619207B1 (en) | 2010-09-22 | 2014-11-12 | Janssen Pharmaceutica, N.V. | 4,7-Dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta secretase (BACE) |
| EP3225697A3 (en) | 2010-12-30 | 2017-11-22 | Foundation Medicine, Inc. | Optimization of multigene analysis of tumor samples |
| US8945829B2 (en) | 2011-03-22 | 2015-02-03 | Cornell University | Distinguishing benign and malignant indeterminate thyroid lesions |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
-
2012
- 2012-06-26 CA CA2840196A patent/CA2840196C/en active Active
- 2012-06-26 JP JP2014518915A patent/JP6154809B2/ja active Active
- 2012-06-26 ES ES12750628.5T patent/ES2580379T3/es active Active
- 2012-06-26 MX MX2013015392A patent/MX341840B/es active IP Right Grant
- 2012-06-26 RU RU2014102357A patent/RU2639509C2/ru active
- 2012-06-26 KR KR1020147001923A patent/KR102082016B1/ko active Active
- 2012-06-26 WO PCT/US2012/044202 patent/WO2013003350A2/en not_active Ceased
- 2012-06-26 AU AU2012275556A patent/AU2012275556B2/en active Active
- 2012-06-26 BR BR112013033488A patent/BR112013033488B8/pt active IP Right Grant
- 2012-06-26 US US14/128,888 patent/US9771617B2/en active Active
- 2012-06-26 EP EP12750628.5A patent/EP2723894B1/en active Active
- 2012-06-26 CN CN201280041358.8A patent/CN103781919B9/zh active Active
-
2013
- 2013-12-19 IL IL230034A patent/IL230034B/en active IP Right Grant
-
2016
- 2016-08-01 JP JP2016150989A patent/JP2016214256A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013033488A2 (pt) | 2017-03-01 |
| WO2013003350A2 (en) | 2013-01-03 |
| IL230034B (en) | 2021-02-28 |
| AU2012275556B2 (en) | 2016-02-04 |
| BR112013033488B8 (pt) | 2022-11-22 |
| MX341840B (es) | 2016-09-05 |
| CA2840196C (en) | 2022-09-20 |
| RU2014102357A (ru) | 2015-08-10 |
| MX2013015392A (es) | 2014-07-14 |
| KR102082016B1 (ko) | 2020-02-26 |
| CN103781919B (zh) | 2017-07-04 |
| RU2639509C2 (ru) | 2017-12-21 |
| EP2723894A2 (en) | 2014-04-30 |
| JP2016214256A (ja) | 2016-12-22 |
| WO2013003350A3 (en) | 2013-04-11 |
| CN103781919A (zh) | 2014-05-07 |
| KR20140044375A (ko) | 2014-04-14 |
| US9771617B2 (en) | 2017-09-26 |
| AU2012275556A1 (en) | 2013-05-02 |
| EP2723894B1 (en) | 2016-05-11 |
| CN103781919B9 (zh) | 2017-09-15 |
| BR112013033488B1 (pt) | 2022-03-03 |
| CA2840196A1 (en) | 2013-01-03 |
| JP6154809B2 (ja) | 2017-06-28 |
| US20140378439A1 (en) | 2014-12-25 |
| JP2014520529A (ja) | 2014-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012275556B2 (en) | MicroRNA biomarkers indicative of Alzheimer's Disease | |
| JP6730525B2 (ja) | 化学組成物とそれを利用する方法 | |
| ES2956732T3 (es) | Métodos de detección de ácidos nucleicos diana en una muestra | |
| ES2890327T3 (es) | Modelos predictivos basados en miARN para el diagnóstico y pronóstico del cáncer de próstata | |
| AU2025204881B2 (en) | Non-coding RNA for detection of cancer | |
| US9677130B2 (en) | Methods to detect and quantify RNA | |
| US11230736B2 (en) | Methods for assessing pregnancy outcome | |
| US20160040253A1 (en) | Method for manufacturing gastric cancer prognosis prediction model | |
| US20200165671A1 (en) | Detecting tissue-specific dna | |
| KR101992539B1 (ko) | miRNA 기반의 인지장애 질환 진단용 조성물 및 방법 | |
| US20140274789A1 (en) | Complex sets of mirnas as non-invasive biomarkers for psoriasis | |
| US20200172970A1 (en) | Dual-probe digital droplet pcr strategy for specific detection of tissue-specific circulating dna molecules | |
| CN102286625B (zh) | 一种与男性生殖功能障碍相关的精浆微小核糖核酸组合及其应用 | |
| JPWO2008149855A1 (ja) | メチル化核酸又は非メチル化核酸を増幅する方法 | |
| CN108531571A (zh) | 用于检测注意力缺陷/过动症的方法和试剂盒 | |
| Fielder | Methylation-Dependent Age-Determination of Environmentally Damaged Samples Using qPCR | |
| WO2026064825A1 (en) | Biomarkers for paratuberculosis | |
| Anand | Using PNA Probes for Hybridization-Based Analysis of miRNAs in Capillary Electrophoresis | |
| AU2013204118A1 (en) | MicroRNA biomarkers indicative of Alzheimer's Disease |